Literature DB >> 15016327

Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape.

Yuichi Nakamura1, Koichi Yamazaki, Satoshi Oizumi, Manabu Nakashima, Takeshi Watanabe, Hirotoshi Dosaka-Akita, Masaharu Nishimura.   

Abstract

RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) inhibits the in vitro growth of receptor-expressing cells and induces apoptosis, which may contribute to the ability of tumor cells to evade host immune surveillance. In this study, we investigated RCAS1 expression in gastric cancer and precancerous lesions by immunohistochemical means. We then analyzed the relationship between RCAS1 expression and clinicopathological variables, and examined whether RCAS1 expression is associated with infiltration of tumor-infiltrating lymphocytes (TILs) and apoptosis of TILs. Of 54 gastric cancers analyzed, RCAS1 expression was positive in 52 (96%) of them. The expression pattern of RCAS1 in gastric cancer cells could be classified as granular staining either enriched in the glandular side of the cytoplasm with polarity (P pattern) or scattered diffusely in the cytoplasm and on the cell membranes (D pattern). Nineteen of 39 intestinal-type carcinomas (49%) showed the P pattern, and all of 13 diffuse type carcinomas (100%) showed the D pattern. In contrast, all RCAS1-positive specimens of gastric adenoma and metaplastic mucosa were of the P pattern. The D pattern of gastric cancers was more frequently recognized in carcinomas with large size (P < 0.01), in those with regional lymph node metastasis (P < 0.05) and in those that had invaded beyond the submucosa (P < 0.01), compared with the P pattern. On the same sections, significantly less TILs were identified in RCAS1-positive areas than RCAS1-negative areas. Furthermore, the rate of apoptosis of TILs was significantly higher in RCAS1-positive areas than in RCAS1-negative areas. The expression and distribution of RCAS1 may be involved in malignant transformation, tumor progression, histological type and tumor escape from host immune surveillance in gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016327     DOI: 10.1111/j.1349-7006.2004.tb02213.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  9 in total

1.  The role of RCAS1 as a biomarker in diagnosing CRC and monitoring tumor recurrence and metastasis.

Authors:  Su-xia Han; Jing Wang; Li-juan Wang; Gui-hua Jin; Xia Ying; Chen-chen He; Xi-jing Guo; Jian-ying Zhang; Ying Zhang; Qing Zhu
Journal:  Tumour Biol       Date:  2014-03-21

2.  Serum-soluble receptor-binding cancer antigen expressed on SiSo cells as a clinical marker in lung cancer.

Authors:  Chun-Hua Xu; Ping Zhan; Yu Zhang; Li-Ke Yu
Journal:  Tumour Biol       Date:  2013-07-24

3.  The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers.

Authors:  Sahin Coban; Hasan Ozkan; Seyfettin Köklü; Osman Yüksel; Muhammed Cem Koçkar; Tarik Akar; Necati Ormeci
Journal:  Can J Gastroenterol       Date:  2006-09       Impact factor: 3.522

4.  The Involvement of RCAS1 in Creating a Suppressive Tumor Microenvironment in Patients with Salivary Gland Adenocarcinoma.

Authors:  Magdalena Dutsch-Wicherek; Agata Lazar; Romana Tomaszewska
Journal:  Cancer Microenviron       Date:  2010-08-20

5.  Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker.

Authors:  Tatiana A Reimer; Ioannis Anagnostopoulos; Bettina Erdmann; Insa Lehmann; Harald Stein; Peter Daniel; Bernd Dörken; Armin Rehm
Journal:  BMC Cancer       Date:  2005-05-17       Impact factor: 4.430

6.  Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories.

Authors:  Yan-Gao Man; Alexander Stojadinovic; Jeffrey Mason; Itzhak Avital; Anton Bilchik; Bjoern Bruecher; Mladjan Protic; Aviram Nissan; Mina Izadjoo; Xichen Zhang; Anahid Jewett
Journal:  J Cancer       Date:  2013-01-05       Impact factor: 4.207

Review 7.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

8.  Increased RCAS1 expression is associated with advanced histopathological stage and poor prognosis in patients with gastric adenocarcinoma.

Authors:  Constantinos Giaginis; Themistoclis Efkarpidis; Paraskevi Alexandrou; Efstratios Patsouris; Gregory Kouraklis; Stamatios Theocharis
Journal:  Dis Markers       Date:  2013-09-03       Impact factor: 3.434

9.  Apoptotic function of tumor-associated antigen RCAS1 in oral squamous cell carcinoma.

Authors:  Hideaki Tanaka; Takeshi Toyoshima; Kenzo Sonoda; Ryoji Kitamura; Masaaki Sasaguri; Shintaro Kawano; Ryota Matsubara; Yuichi Goto; Seiji Nakamura
Journal:  J Transl Med       Date:  2014-05-06       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.